# Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors

> **NCT07570745** · PHASE2 · RECRUITING · sponsor: **Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 82 (estimated)

## Conditions studied

- Graft-Versus-Host Disease(GVHD)
- Bone Marrow Transplantation

## Interventions

- **DRUG:** Low-dose ATG + PTCy + Ivarmacitinib

## Key facts

- **NCT ID:** NCT07570745
- **Lead sponsor:** Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05-01
- **Primary completion:** 2028-05-01
- **Final completion:** 2029-05-01
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07570745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07570745, "Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT07570745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*